Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials
Malcolm Begg,J Nicole Hamblin,Emily Jarvis,Glyn Bradley,Stephen Mark,David Michalovich,Mark Lennon,Hannah E Wajdner,Augustin Amour,Robert Wilson,Ken Saunders,Rikako Tanaka,Saki Arai,Teresa Tang,Cedric Van Holsbeke,Jan De Backer,Wim Vos,Ingrid L Titlestad,J Mark FitzGerald,Kieran Killian,Jean Bourbeau,Claude Poirier,François Maltais,Anthony Cahn,Edith M Hessel,Hannah Wajdner
DOI: https://doi.org/10.2147/COPD.S309303
2021-06-03
International Journal of COPD
Abstract:Malcolm Begg, 1 J Nicole Hamblin, 1 Emily Jarvis, 2 Glyn Bradley, 3 Stephen Mark, 4 David Michalovich, 5 Mark Lennon, 6 Hannah E Wajdner, 5 Augustin Amour, 5 Robert Wilson, 1 Ken Saunders, 5 Rikako Tanaka, 7 Saki Arai, 7 Teresa Tang, 8 Cedric Van Holsbeke, 9 Jan De Backer, 9 Wim Vos, 9 Ingrid L Titlestad, 10 J Mark FitzGerald, 11 Kieran Killian, 12 Jean Bourbeau, 13 Claude Poirier, 14 François Maltais, 15 Anthony Cahn, 1 Edith M Hessel 1 1 Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK; 2 Biostatistics, GlaxoSmithKline R&D, Stevenage, UK; 3 Computational Biology, Medicinal Science and Technology, GlaxoSmithKline, Stevenage, UK; 4 Study Management, Clinical Development, GlaxoSmithKline, Mississauga, ON, Canada; 5 Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK; 6 Nonclinical and Translational Statistics, GlaxoSmithKline, Stevenage, UK; 7 Data Management & Strategy, Clinical Development, GlaxoSmithKline, Tokyo, Japan; 8 Pharma Safety, Clinical Development, GlaxoSmithKline, Brentford, Middlesex, UK; 9 FLUIDDA nv, Kontich, 2550, Belgium; 10 Department of Respiratory Medicine, Odense University Hospital and University of Southern Denmark, Odense, Denmark; 11 Centre for Heart and Lung Health, University of British Columbia, Vancouver, BC, Canada; 12 Cardiorespiratory Research Laboratory, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada; 13 Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, QC, Canada; 14 Department of Medicine, Respiratory Medicine Division, University of Montreal, Montreal, QC, Canada; 15 Institut Universitaire de Cardiologie et de Pneumologie de Québe, Université Laval, Quebec City, QC, Canada Correspondence: Malcolm Begg Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, Herts, UK Email Background: Inhibition of phosphoinositide 3-kinase δ (PI3Kδ) exerts corrective effects on the dysregulated migration characteristics of neutrophils isolated from patients with chronic obstructive pulmonary disease (COPD). Objective: To develop novel, induced sputum endpoints to demonstrate changes in neutrophil phenotype in the lung by administering nemiralisib, a potent and selective inhaled PI3Kδ inhibitor, to patients with stable COPD or patients with acute exacerbation (AE) of COPD. Methods: In two randomized, double-blind, placebo-controlled clinical trials patients with A) stable COPD (N=28, randomized 3:1) or B) AECOPD (N=44, randomized 1:1) received treatment with inhaled nemiralisib (1mg). Endpoints included induced sputum at various time points before and during treatment for the measurement of transcriptomics (primary endpoint), inflammatory mediators, functional respiratory imaging (FRI), and spirometry. Results: In stable COPD patients, the use of nemiralisib was associated with alterations in sputum neutrophil transcriptomics suggestive of an improvement in migration phenotype; however, the same nemiralisib-evoked effects were not observed in AECOPD. Inhibition of sputum inflammatory mediators was also observed in stable but not AECOPD patients. In contrast, a placebo-corrected improvement in forced expiratory volume in 1 sec of 136 mL (95% Credible Intervals − 46, 315mL) with a probability that the true treatment ratio was > 0% (Pr(θ> 0)) of 93% was observed in AECOPD. However, FRI endpoints remained unchanged. Conclusion: We provide evidence for nemiralisib-evoked changes in neutrophil migration phenotype in stable COPD but not AECOPD, despite improving lung function in the latter group. We conclude that induced sputum can be used for measuring evidence of alteration of neutrophil phenotype in stable patients, and our study provides a data set of the sputum transcriptomic changes during recovery from AECOPD. Keywords: nemiralisib, sputum, transcriptomics, COPD exacerbations, PI3Kdelta The mechanisms of action of novel immunomodulator drugs are far removed from established clinical efficacy endpoints, hence translational endpoints are helpful to build confidence in the pharmacology of the drug and enables better interpretation of study outcomes. We set out to explore the consequence of treatment with the inhaled phosphoinositide 3-kinase δ (PI3Kδ) inhibitor nemiralisib, which was administered to patients suffering from -Abstract Truncated-